多组学与合成业务的表现也未能幸免。该业务营收为2.79亿元，同比下降8.30%，其中科技服务业务中的 RNA类产品和合成业务的营收分别下降约34%和29%。这一下滑与欧美地区科技服务业务的进一步萎缩密 切相关，地缘政治因素对海外市场的负面影响在此板块表现得尤为明显。 昨天（8月22日）晚间，深圳华大基因股份有限公司（300676）发布了其2025年半年度报告。 报告期内，华大基因实现营业收入16.31亿元，相较于去年同期的18.71亿元，同比下降了12.82%；归属于 上市公司股东的净利润仅为577.82万元，同比骤降68.25%。若扣除非经常性损益，净利润更是由去年同期 的121.43万元，转为亏损3048.81万元，同比下降幅度高达2610.77%，这表明公司主营业务的盈利能力正承 受着前所未有的巨大压力。 此外，经营活动产生的现金流量净额为-4.14亿元，同比下降414.23%，显示出公司经营性现金流状况持续 恶化，这无疑给公司的日常运营和未来投资带来了额外的挑战。 业绩的下滑并非偶然，而是多重因素交织作用的结果，具体体现在华大基因各大主营业务板块的表现分化 上。作为公司的核心支柱，生育健康业务在报告期 ...

业绩的下滑并非偶然，而是多重因素交织作用的结果，具体体现在华大基因各大主营业务板块的表现分 化上。作为公司的核心支柱，生育健康业务在报告期内面临严峻考验。该业务实现营收4.26亿元，同比 大幅下降29.80%。报告指出，这一下滑主要源于无创产前基因检测业务的营收同比下降约35%。尽管公 司在技术和市场策略上持续加强院内布局，但随着市场竞争加剧，无创产前基因检测基础版产品的价格 持续走低，盈利空间被压缩。 同样面临挑战的还有肿瘤与慢病防控业务。该业务上半年实现营收1.80亿元，同比下降27.52%，其中肠 癌检测业务营收下降约42%是主要拖累。报告对此的解释是，与民生项目相关的合作主要集中在下半年 续签和启动，因此上半年采样工作尚未全面铺开。尽管如此，这一下滑也反映出该业务对外部合作的依 赖性较强。为了应对这一被动局面，华大基因表示，正加大对C端市场的销售布局，试图加速向自检产 品直销模式转型，以增强业务的独立性和抗风险能力。 多组学与合成业务的表现也未能幸免。该业务营收为2.79亿元，同比下降8.30%，其中科技服务业务中 的RNA类产品和合成业务的营收分别下降约34%和29%。这一下滑与欧美地区科技服务业务 ...

Core Insights - BGI Genomics reported a revenue of 1.631 billion yuan and a net profit of 5.7782 million yuan for the first half of 2025, with a significant recovery in profitability in Q2, achieving a net profit of 58.4733 million yuan, a year-on-year increase of 908.64% [1] - The company is leveraging its proprietary platforms and big data advantages to drive product upgrades and accelerate global market expansion amid a reshaping healthcare industry [1][3] Business Segments - Precision Medicine: Revenue reached 696 million yuan, a year-on-year increase of 4.80%, with significant growth in emerging markets such as Latin America and South Asia [1][2] - Reproductive Health: Revenue was 426 million yuan, with a 15% increase in genetic disease testing services, and strong growth in non-invasive prenatal testing in overseas markets [2] - Cancer and Chronic Disease Prevention: Revenue was 180 million yuan, with ongoing collaborations for colorectal cancer projects and a focus on direct sales of colorectal cancer testing products [2] - Infection Control: Revenue was 38 million yuan, with a remarkable 242% increase in revenue from PTseq products based on targeted high-throughput sequencing technology [2] - Multi-Omics and Synthesis: Revenue reached 279 million yuan, with single-cell sequencing showing a significant growth rate of approximately 110% [2] Technological Advancements - The company is entering an AI-enabled era in the genetic testing industry, actively developing digital business growth through "genetic technology + data elements" [3] - BGI Genomics has launched the SIRO high-throughput sequencing AI solution and OmicsOne intelligent analysis platform, ensuring data localization and security [3] - The ChatGeneT platform is being industrialized to enhance clinical interpretation and consultation, improving efficiency in outpatient services [3] - The "i99 Smart Health" multi-omics health management system has been introduced, providing personalized health management solutions using AI technology [4]

深圳华大基因股份有限公司 2025 年半年度报告全文 深圳华大基因股份有限公司 深圳华大基因股份有限公司 2025 年半年度报告全文 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人赵立见、主管会计工作负责人王玉珏及会计机构负责人(会计 主管人员)张祖菊声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及的未来发展战略与规划、经营计划与目标等前瞻性陈述，不构 成公司对投资者的实质承诺。投资者及相关人士均应对此保持足够的风险认 识，并应理解计划、预测与承诺之间的差异。公司在本报告第三节"管理层讨 论与分析"之"十、公司面临的风险和应对措施" 部分，详细描述了公司经营 中可能存在的风险及应对措施，敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 深圳华大基因股份有限公司 2025 年半年度报告全文 深圳华大基因股份有限公司 2025 年半年度报告全文 一、载有公司法定代表人、主管会计工作负责人、会计机构负责 ...

| 深圳华大基因股份有限公司 | | | 2025 年半年度报告摘要 | | | --- | --- | --- | --- | --- | | 证券代码：300676 证券简称：华大基因 | | | 公告编号：2025- | | | 045 | | | | | | 深圳华大基因股份有限公司 2025 | 年半年度报告摘要 | | | | | 一、重要提示 | | | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划， | | | | | | 投资者应当到 | | | | | | 证监会指定媒体仔细阅读半年度报告全文。 | | | | | | 所有董事均已出席了审议本报告的董事会会议。 | | | | | | 非标准审计意见提示 | | | | | | □适用 ?不适用 | | | | | | 董事会审议的报告期利润分配预案或公积金转增股本预案 | | | | | | □适用 ?不适用 | | | | | | 公司计划不派发现金红利，不送红股，不以公积金转增股本。 | | | | | | 董事会决议通过的本报告期优先股利润分配预案 | | | | | | □适 ...

Core Viewpoint - Jiangsu Province is initiating a centralized procurement process for tumor gene testing services to reduce costs and regulate the industry, following a successful model for non-invasive prenatal genetic testing [1][2]. Group 1: Centralized Procurement Details - The procurement period is set for two years, focusing on various clinical samples using fluorescence quantitative PCR and high-throughput sequencing methods for tumor gene testing [2]. - The maximum effective bid for fluorescence quantitative analysis is set at 280 yuan per single site, while for high-throughput sequencing, it is 800 yuan per gene [2][3]. - The pricing structure aims to ensure that companies can still cover costs, although concerns exist regarding the potential impact on testing quality due to lower prices [3][5]. Group 2: Industry Impact and Adjustments - The centralized procurement is expected to disrupt the previous high-price model, allowing larger companies to negotiate better with hospitals, while smaller firms may struggle to compete [4][8]. - There is a possibility that companies might bid below cost to win contracts, which could negatively affect the quality of testing services [5][6]. - The procurement process is anticipated to reduce gray areas in the industry, as it eliminates the need for high commissions to doctors, thereby increasing price transparency [7][8]. Group 3: Financial Implications for Stakeholders - Sales personnel's income is likely to decrease significantly due to the reduced commission structure following centralized procurement, impacting their overall earnings [8]. - The previous practice of providing substantial kickbacks to doctors has diminished, with current rates dropping to around 20% for retail and below 15% for inpatient sales [6][8].

证券日报网讯 8月20日晚间，贝瑞基因发布公告称，近日，公司之全资子公司杭州贝瑞和康基因诊断技 术有限公司向杭州联合农村商业银行股份有限公司高沙支行申请综合授信4，000万元，授信期限1年。 公司同意为杭州贝瑞使用上述授信所形成的债务提供连带责任保证担保。截至本公告日，公司及控股子 公司对外担保总额为人民币35，700万元（含本次担保），占公司最近一期经审计净资产比例为 21.26%。 （编辑 李家琪） ...

Core Viewpoint - The company, Beirui Gene, is seeking a credit facility of 40 million yuan for its wholly-owned subsidiary, Hangzhou Beirui, to support its operations and ensure stable development [1][2]. Financial Overview - As of March, Hangzhou Beirui reported total assets of 1.106 billion yuan, total liabilities of 266 million yuan, and net assets of 840 million yuan [2]. - In the first quarter, Hangzhou Beirui's unaudited revenue and net profit were 90.06 million yuan and 4.49 million yuan, respectively [2]. - The total amount of external guarantees provided by Beirui Gene and its subsidiaries is 357 million yuan, which is 21.26% of the latest audited net assets [2]. Performance Challenges - Beirui Gene has faced continuous performance pressure since 2021, with revenues declining from 1.422 billion yuan in 2021 to an expected 1.078 billion yuan in 2024, and net profits turning negative [4]. - The company anticipates a net loss of 22 million to 33 million yuan in the first half of 2025, compared to a profit of 9.26 million yuan in the same period last year [4]. Market Position and Future Plans - The company focuses on the reproductive health sector, with significant commercial success in prenatal testing, while the prenatal and newborn markets are still in the early stages [5]. - Beirui Gene plans to leverage artificial intelligence and its advanced sequencing technology to expand into more complex genetic testing services and provide direct health services to consumers [5].

（文章来源：每日经济新闻） 2024年1至12月份，贝瑞基因的营业收入构成为：基因检测行业占比100.0%。 贝瑞基因（SZ 000710，收盘价：14.52元）8月20日晚间发布公告称，公司第十届第十六次董事会会议 于2025年8月20日在北京市昌平区生命园路4号院5号楼8层会议室以现场与通讯会议相结合的方式召开。 会议审议了《关于为全资子公司提供担保的议案》等文件。 ...

2024年1至12月份，贝瑞基因的营业收入构成为：基因检测行业占比100.0%。 （文章来源：每日经济新闻） 贝瑞基因（SZ 000710，收盘价：14.52元）8月20日晚间发布公告称，近日，公司全资子公司杭州贝瑞 向杭州联合农村商业银行股份有限公司高沙支行申请综合授信4000万元，授信期限1年。公司同意为杭 州贝瑞使用上述授信所形成的债务提供连带责任保证担保。 截至本公告日，公司及控股子公司对外担保总额为人民币3.57亿元，占公司最近一期经审计净资产比例 为21.26%；其中公司及其控股子公司对合并报表外单位提供的担保总余额为1.47亿元，占公司最近一期 经审计净资产的比例为8.75%。 ...